Current pharmacological treatments for COVID‐19: What's next?

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286

Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-Infected pneumonia in Wuhan, China

Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148

La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19

Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575

COVID-19: consider cytokine storm syndromes and immunosuppression

Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958

First case of 2019 novel coronavirus in the United States

Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030

Gout-associated uric acid crystals activate the NALP3 inflammasome

Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187

Untitled work

Guo (2020) · doi:10.1186/s40779-020-00240-0 · Cited by 4,735

Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records

Chen, H., Guo, J., Wang, C., Luo, F., Yu, X., Zhang, W., Li, J., Zhao, D., Xu, D., Gong, Q., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30360-3 · Cited by 3,919

Coronaviruses: An Overview of Their Replication and Pathogenesis

Fehr, A. R., & Perlman, S. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2438-7_1 · Cited by 3,787

Effective treatment of severe COVID-19 patients with tocilizumab

Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005615117 · Cited by 2,647

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Gao, J., Tian, Z., & Yang, X. (2020) · BioScience Trends · doi:10.5582/bst.2020.01047 · Cited by 2,590

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.

Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104787 · Cited by 2,179

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Vincent, M. J., Bergeron, E., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005) · Virology Journal · doi:10.1186/1743-422x-2-69 · Cited by 1,811

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,738

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

Harding, S. D., Sharman, J. L., Faccenda, E., Southan, C., Pawson, A. J., Ireland, S., Gray, A. J. G., Bruce, L., Alexander, S. P. H., Anderton, S., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1121 · Cited by 1,646

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Rawling, M., Savory, E., & Stebbing, J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30304-4 · Cited by 1,456

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

Agostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,416

Discovering drugs to treat coronavirus disease 2019 (COVID-19)

Dong, L., Hu, S., & Gao, J. (2020) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2020.01012 · Cited by 1,390

Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance

World Health Organization (2020) · Pediatria i Medycyna Rodzinna · doi:10.15557/pimr.2020.0003 · Cited by 1,329

Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome

WONG, C. K., LAM, C. W. K., WU, A. K. L., IP, W. K., LEE, N. L. S., CHAN, I. H. S., LIT, L. C. W., HUI, D. S. C., CHAN, M. H. M., CHUNG, S. S. C., et al. (2004) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2004.02415.x · Cited by 1,274

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China

Zhang, W., Zhao, Y., Zhang, F., Wang, Q., Li, T., Liu, Z., Wang, J., Qin, Y., Zhang, X., Yan, X., et al. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108393 · Cited by 1,266

SARS: systematic review of treatment effects

Stockman, L. J., Bellamy, R., & Garner, P. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030343 · Cited by 1,217

A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19

Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A., & Einav, S. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.03.005 · Cited by 1,160

COVID-19: combining antiviral and anti-inflammatory treatments

Stebbing, J., Phelan, A., Griffin, I., Tucker, C., Oechsle, O., Smith, D., & Richardson, P. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30132-8 · Cited by 1,117

MERS, SARS and other coronaviruses as causes of pneumonia

Yin, Y., & Wunderink, R. G. (2018) · Respirology · doi:10.1111/resp.13196 · Cited by 1,095

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

FURUTA, Y., KOMENO, T., & NAKAMURA, T. (2017) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.93.027 · Cited by 1,070

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19

Colson, P., Rolain, J.-M., Lagier, J.-C., Brouqui, P., & Raoult, D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105932 · Cited by 937

Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study

Elfiky, A. A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117592 · Cited by 923

The convalescent sera option for containing COVID-19

Casadevall, A., & Pirofski, L.-A. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138003 · Cited by 903

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

de Wit, E., Feldmann, F., Cronin, J., Jordan, R., Okumura, A., Thomas, T., Scott, D., Cihlar, T., & Feldmann, H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922083117 · Cited by 887

Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial

Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., et al. (2020) · doi:10.1101/2020.03.17.20037432 · Cited by 852

Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial

Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.683296 · Cited by 849

Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients

Ling, Y., Xu, S.-B., Lin, Y.-X., Tian, D., Zhu, Z.-Q., Dai, F.-H., Wu, F., Song, Z.-G., Huang, W., Chen, J., et al. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000774 · Cited by 803

The 2019‐new coronavirus epidemic: Evidence for virus evolution

Benvenuto, D., Giovanetti, M., Ciccozzi, A., Spoto, S., Angeletti, S., & Ciccozzi, M. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25688 · Cited by 713

THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein‐coupled receptors

Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14748 · Cited by 702

Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV

Xu, J., Zhao, S., Teng, T., Abdalla, A. E., Zhu, W., Xie, L., Wang, Y., & Guo, X. (2020) · Viruses · doi:10.3390/v12020244 · Cited by 683

Center for Drug Evaluation and Research

National Cancer Institute (2020) · Definitions · doi:10.32388/doq9wu · Cited by 674

[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].

Chen, J., Liu, D., Liu, L., Liu, P., Xu, Q., Xia, L., Ling, Y., Huang, D. F., Song, S., Zhang, D., et al. (2020) · PubMed · doi:10.3785/j.issn.1008-9292.2020.03.03 · Cited by 664

Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis

Gralinski, L. E., Sheahan, T. P., Morrison, T. E., Menachery, V. D., Jensen, K., Leist, S. R., Whitmore, A., Heise, M. T., & Baric, R. S. (2018) · mBio · doi:10.1128/mbio.01753-18 · Cited by 655

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

Keyaerts, E., Vijgen, L., Maes, P., Neyts, J., & Ranst, M. V. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.085 · Cited by 649

Protease inhibitors targeting coronavirus and filovirus entry

Zhou, Y., Vedantham, P., Lu, K., Agudelo, J., Carrion, R., Nunneley, J. W., Barnard, D., Pöhlmann, S., McKerrow, J. H., Renslo, A. R., et al. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.01.011 · Cited by 583

Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)

(2020) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-200220-0773 · Cited by 486

COVID-19 infection and rheumatoid arthritis: Faraway, so close

Favalli, E. G., Ingegnoli, F., De Lucia, O., Cincinelli, G., Cimaz, R., & Caporali, R. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102523 · Cited by 454

THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets

Alexander, S. P. H., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14747 · Cited by 423

Tocilizumab: A review in rheumatoid arthritis

Scott, L. J. (2017) · Drugs · doi:10.1007/s40265-017-0829-7 · Cited by 419

Mechanism of Action of Colchicine in the Treatment of Gout

Dalbeth, N., Lauterio, T. J., & Wolfe, H. R. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.07.017 · Cited by 416

Favipiravir as a potential countermeasure against neglected and emerging RNA viruses

Delang, L., Abdelnabi, R., & Neyts, J. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.03.003 · Cited by 388

Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model

Yan, Y., Zou, Z., Sun, Y., Li, X., Xu, K.-F., Wei, Y., Jin, N., & Jiang, C. (2013) · Cell Research · doi:10.1038/cr.2012.165 · Cited by 353

Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension

Petkov, V., Mosgoeller, W., Ziesche, R., Raderer, M., Stiebellehner, L., Vonbank, K., Funk, G.-C., Hamilton, G., Novotny, C., Burian, B., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17500 · Cited by 352

Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression

Zhu, L., Xu, X., Ma, K., Yang, J., Guan, H., Chen, S., Chen, Z., & Chen, G. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15869 · Cited by 333

Antiviral Activity of Chloroquine against Human Coronavirus OC43 Infection in Newborn Mice

Keyaerts, E., Li, S., Vijgen, L., Rysman, E., Verbeeck, J., Van Ranst, M., & Maes, P. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01509-08 · Cited by 311

Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China

Kruse, R. L. (2020) · F1000Research · doi:10.12688/f1000research.22211.1 · Cited by 311

Mannose-Binding Lectin in Severe Acute Respiratory Syndrome Coronavirus Infection

Ip, W. K. E., Chan, K. H., Law, H. K. W., Tso, G. H. W., Kong, E. K. P., Wong, W. H. S., To, Y. F., Yung, R. W. H., Chow, E. Y., Au, K. L., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/429631 · Cited by 284

The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines

Shang, W., Yang, Y., Rao, Y., & Rao, X. (2020) · npj Vaccines · doi:10.1038/s41541-020-0170-0 · Cited by 275

Camrelizumab: First Global Approval

Markham, A., & Keam, S. J. (2019) · Drugs · doi:10.1007/s40265-019-01167-0 · Cited by 265

Corticosteroids as adjunctive therapy in the treatment of influenza

Rodrigo, C., Leonardi-Bee, J., Nguyen-Van-Tam, J., & Lim, W. S. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010406.pub2 · Cited by 264

Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial

And the MIRACLE trial group, Arabi, Y. M., Alothman, A., Balkhy, H. H., Al-Dawood, A., AlJohani, S., Al Harbi, S., Kojan, S., Al Jeraisy, M., Deeb, A. M., et al. (2018) · Trials · doi:10.1186/s13063-017-2427-0 · Cited by 253

Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy In Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use

Manchikanti, L. (2020) · Pain Physician · doi:10.36076/ppj.2020/23/e71 · Cited by 227

Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects

Bekerman, E., Neveu, G., Shulla, A., Brannan, J., Pu, S.-Y., Wang, S., Xiao, F., Barouch-Bentov, R., Bakken, R. R., Mateo, R., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89857 · Cited by 226

Coronaviruses: Methods and Protocols

(2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2438-7 · Cited by 209

Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak

Sung, J. J. Y. (2004) · Thorax · doi:10.1136/thx.2003.014076 · Cited by 185

Liver and Kidney Injuries in COVID-19 and Their Effects on Drug Therapy; a Letter to Editor.

Rismanbaf, A., & Zarei, S. (2020) · Archives of Academic Emergency Medicine · doi:10.22037/aaem.v8i1.590 · Cited by 175

Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?

Jawhara, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072272 · Cited by 163

Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial

Bian, H., Zheng, Z.-H., Wei, D., Zhang, Z., Kang, W.-Z., Hao, C.-Q., Dong, K., Kang, W., Xia, J.-L., Miao, J.-L., et al. (2020) · medRxiv · doi:10.1101/2020.03.21.20040691 · Cited by 158

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review

Feng, W., Zong, W., Wang, F., & Ju, S. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01218-1 · Cited by 158

Vaccine designers take first shots at COVID-19

Cohen, J. (2020) · Science · doi:10.1126/science.368.6486.14 · Cited by 152

Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial

and the Saudi Critical Care Trials group, Arabi, Y. M., Asiri, A. Y., Assiri, A. M., Jokhdar, H., Alothman, A. F., Balkhy, H. H., AlJohani, S. M., Harbi, S. A. A., Kojan, S. M., et al. (2020) · Trials · doi:10.1186/s13063-019-3846-x · Cited by 128

Comparison of the Antiviral Activity in vitro of some Non-steroidal Anti-inflammatory Drugs

Inglot, A. D. (1969) · Journal of General Virology · doi:10.1099/0022-1317-4-2-203 · Cited by 121

Retinal toxicity in long term hydroxychloroquine treatment.

Mavrikakis, M., Papazoglou, S. N., Sfikakis, P. P., Vaiopoulos, G., & Rougas, K. (1996) · Annals of the Rheumatic Diseases · doi:10.1136/ard.55.3.187 · Cited by 119

Emerging agents and regimens for hepatocellular carcinoma

Zhu, X., & Sun, H. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0794-6 · Cited by 118

Tubulin bound to colchicine forms polymers different from microtubules.

Andreu, J. M., & Timasheff, S. N. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.22.6753 · Cited by 111

Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: a rationale for use of low‐dose colchicine

Chia, E. W., Grainger, R., & Harper, J. L. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.20 · Cited by 110

The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)-related critical illness

on behalf of the Canadian Critical Care Trials Group H1N1 Collaborative, Delaney, J. W., Pinto, R. L., Long, J. K., Lamontagne, F., Adhikari, N. K. J., Kumar, A., Marshall, J. C., Cook, D. J., Jouvet, P. A., et al. (2016) · Critical Care · doi:10.1186/s13054-016-1230-8 · Cited by 99

Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review

Gbinigie, O. A., & Frie, K. (2020) · BJGP Open · doi:10.3399/bjgpopen20x101069 · Cited by 99

Influence of FcγRIIA and MBL polymorphisms on severe acute respiratory syndrome

Yuan, F. F., Tanner, J. A., Chan, P. K. S., Biffin, S., Dyer, W. B., Geczy, A. F., Tang, J. W.-T., Hui, D. S. C., Sung, J. J. �., & Sullivan, J. S. (2005) · Tissue Antigens · doi:10.1111/j.1399-0039.2005.00476.x · Cited by 91

Vascular Endothelial Growth Factor in Acute Lung Injury and Acute Respiratory Distress Syndrome

Barratt, S. L., Medford, A. R. L., & Millar, A. (2013) · Respiration · doi:10.1159/000356034 · Cited by 82

Thalidomide and Thalidomide Analogs Reduce HIV Type 1 Replication in Human Macrophages in Vitro

Moreira, A. L., Corral, L. G., Ye, W., JOHNSON, B., STIRLING, D., Muller, G. W., Freedman, V. H., & Kaplan, G. (1997) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1997.13.857 · Cited by 76

Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations

Soliman, E. Z., Lundgren, J. D., Roediger, M. P., Duprez, D. A., Temesgen, Z., Bickel, M., Shlay, J. C., Somboonwit, C., Reiss, P., Stein, J. H., et al. (2010) · AIDS · doi:10.1097/qad.0b013e328341dcc0 · Cited by 73

Quantity does not equal quality: Scientific principles cannot be sacrificed

Rzymski, P., Nowicki, M. O., Mullin, G. E., Abraham, A., Rodríguez‐Román, E., Petzold, M. B., Bendau, A., Sahu, K. K., Ather, A., Naviaux, A.-F., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106711 · Cited by 71

Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases

Mayence, A., & Eynde, J. J. V. (2019) · Pharmaceuticals · doi:10.3390/ph12010037 · Cited by 56

Corticosteroids as adjunctive therapy in the treatment of influenza

Rodrigo, C., Leonardi‐Bee, J., Nguyen‐Van‐Tam, J. S., & Lim, W. S. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010406 · Cited by 21

Novel thalidomide analogues from diamines inhibit pro-inflammatory cytokine production and CD80 expression while enhancing IL-10

Mazzoccoli, L., Cadoso, S. H., Amarante, G. W., Souza, M. V. N. D., Domingues, R., Machado, M. A., de Almeida, M. V., & Teixeira, H. C. (2012) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2012.05.001 · Cited by 18

The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia

(2020) · Case Medical Research · doi:10.31525/ct1-nct04273529 · Cited by 4

Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020) · JAMA · doi:10.1001/jama.2020.12839 · Cited by 4,609

The COVID-19 pandemic and physical activity

Woods, J. A., Hutchinson, N. T., Powers, S. K., Roberts, W. O., Gomez-Cabrera, M. C., Radak, Z., Berkes, I., Boros, A., Boldogh, I., Leeuwenburgh, C., et al. (2020) · Sports Medicine and Health Science · doi:10.1016/j.smhs.2020.05.006 · Cited by 632

Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study

Pablos, J. L., Galindo, M., Carmona, L., Lledó, A., Retuerto, M., Blanco, R., Gonzalez-Gay, M. A., Martinez-Lopez, D., Castrejón, I., Alvaro-Gracia, J. M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218296 · Cited by 238